Trevi Therapeutics, Inc. Increase (Decrease) in Deferred Leasing Fees
Trevi Therapeutics, Inc. (TRVI) reported Increase (Decrease) in Deferred Leasing Fees of -$43.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLeasingFees · last filed 2020-03-16
- Trevi Therapeutics, Inc. increase (decrease) in deferred leasing fees for the quarter ending 2018-12-31 was -$45.00K.
- Trevi Therapeutics, Inc. increase (decrease) in deferred leasing fees for fiscal 2018 was -$43.00K.
| Period end | Increase (Decrease) in Deferred Leasing Fees 3 month | Increase (Decrease) in Deferred Leasing Fees 9 month | Increase (Decrease) in Deferred Leasing Fees 12 month |
|---|---|---|---|
| 2018-12-31 | -$45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$43.00K 10-K · filed 2020-03-16 | |
| 2018-09-30 | $2.00K 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |